| 查看: 3884 | 回复: 17 | |||||
[交流]
达比加群酯的SWOT分析项
|
|||||
|
老大让我做一个SWOT分析，这对一个没有THOMSON、没有Pharmaproject的立项工作者来说，只能空手套白狼了，暂时只想出以下几个分析项，请各位虫友补充啦。 S分析 用药方法的便利性 出血安全性得到FDA、EMA等机构的屡次肯定 曾经获得FDA下属委员会全票支持 其对卒中的预防效果明显优于华法林 有间接比较研究显示，达比加群酯的成本-效益特征与有效性特征优于利伐沙班 先后在德国和加拿大被授予Prix Galien最佳药物奖 曾经获得NICE的有条件推荐 上市后市场表现强劲，已经实现了重磅炸弹级别的销售额 W分析 出血事件—达比加群酯挥之不去的阴影 肾功能损伤与P-gp是达比加群酯在其用药过程中需要调整剂量的主要因素 RE-ALLGN失败，使得人工心脏瓣膜成为达比加群酯的禁忌症之一 价格昂贵 O分析 适应证发病率高，用药市场规模庞大 需要开发新的药物，以弥补华法林的不足 利伐沙班于ROCKET-AF试验中仅证实与华法林相比的非劣性 T分析 将面临来自阿哌沙班、利伐沙班、依度沙班的激烈竞争 [ Last edited by williamxiang on 2013-4-3 at 16:31 ] |
回复此楼» 收录本帖的淘帖专辑推荐
 研发工艺 | 泮托拉唑 |
» 猜你喜欢
基于AI智能算法的装备结构可靠性分析与优化设计技术
已经有0人回复
-
求助求助
已经有0人回复
-
药理学论文润色/翻译怎么收费?
已经有211人回复
-
农业资源与环境、智慧农业专业本科生毕业论文课题选题求助
已经有1人回复
-
人工智能赋能聚合物及复合材料模型应用与实践
已经有0人回复
-
各国和国际组织现行药典注射用水质量标准
已经有0人回复
-
求助用微谱数据库查询
已经有0人回复
-
计算化学与人工智能驱动的MOFs性能预测与筛选技术
已经有0人回复
-
研三实验求指导
已经有0人回复
-
金属材料多尺度计算模拟技术与应用：微观机理到宏观性能的集成工作
已经有0人回复
-
2026申请考核博士自荐-蛋白质组学/AI/药物设计/AIDD/化学生物学
已经有1人回复
» 本主题相关价值贴推荐，对您同样有帮助:
- 达比加群酯在中国获批
已经有17人回复
- 达比加群酯经过碱降解后产物会是什么结构？
已经有10人回复
- 达比加群酯甲磺酸盐 颜色
已经有10人回复
» 抢金币啦！回帖就可以得到:
-
985教授征女友
+1/248
-
大连海事大学轮机学院博士名额1个
+1/186
-
江西理工大学联合中国科学院赣江创新研究院招收2026级博士研究生
+1/81
-
人间烟火，实则就是追求最简单的快乐
+1/75
-
山东征女友，坐标济南
+1/68
-
好玩的不敢搞，能搞的不挣钱，能挣钱的我不会做
+1/66
-
澳大利亚麦考瑞大学(Macquarie University)国际博士硕士全额奖学金-计算机-26年中开学
+1/32
-
同济大学脑机智能团队脑机接口方向招生招聘
+1/28
-
上海交通大学-宁波东方理工大学联合培养博士生 – 力学
+1/25
-
上海交大药学院侯四化课题组招收2名2026年秋季入学申请-考核制博士生
+1/24
-
中国科学技术大学环境系招生
+1/9
-
中北大学冯瑞教授*开山大弟子*招募
+1/9
-
怎么发布了求助贴了， 一发就转到删除栏了
+1/8
-
宁波诺丁汉大学招收26年秋/27年春固废协同转化与低碳冶金方向全奖博士生
+1/7
-
墨尔本大学(QS13)急招CSC博士(补齐全奖)/访问学者/博士后(生物医学材料/器官芯片)
+1/7
-
澳科大招收2026年秋季药物递送/生物材料方向硕士研究生（3月5日18:00报名截止）
+1/7
-
华南师范大学（211）- 光电科学与工程学院 - 申请审核制（2026年4-5月份面试考核）
+2/6
-
澳科大药学院诚招2026年秋季药剂学/生物材料硕士研究生（2026年3月5日报名截止）
+1/4
-
队友
+1/3
-
大连海事大学船舶洁净能源研究中心2026年博士研究生招生启事
+1/1
★ ★ ★ ★ ★ ★ ★ ★
小木虫: 金币+0.5, 给个红包，谢谢回帖
痴夷子皮: 金币+2, 谢谢交流，欢迎常来哦。 2013-04-07 08:32:30
williamxiang: 金币+5 2013-04-07 09:53:30
小木虫: 金币+0.5, 给个红包，谢谢回帖
痴夷子皮: 金币+2, 谢谢交流，欢迎常来哦。 2013-04-07 08:32:30
williamxiang: 金币+5 2013-04-07 09:53:30
|
楼上的就是来自TP中达比加群酯的SWOT分析。 给楼主个站内链接：http://muchong.com/bbs/viewthread.php?tid=5319066 建议：做产品SWOT分析的时候可结合国内情况，行业情况及本公司情况三级，给出相应的分析。 楼主对这个产品所述的SWOT分析，已相当专业了！除了专业方面的应该还有些上述建议的其他的。 个人意见，仅供参考！ |
9楼2013-04-04 00:12:48
★ ★ ★
小木虫: 金币+0.5, 给个红包，谢谢回帖
痴夷子皮: 金币+2, 谢谢交流，欢迎常来哦。 2013-04-07 08:32:18
小木虫: 金币+0.5, 给个红包，谢谢回帖
痴夷子皮: 金币+2, 谢谢交流，欢迎常来哦。 2013-04-07 08:32:18
|
Strengths The first novel anticoagulant to secure approval for stroke prevention in atrial fibrillation (AF), entering the US market in November 2010 No requirement for anticoagulation monitoring and dose adjustment, and no food effect In the RE-LY trial in AF, Pradaxa showed comparable to superior efficacy in stroke prevention, compared with warfarin, with equal to lower bleeding risk A subgroup analysis from RE-LY showed that Pradaxa 150 mg bid reduced the rate of stroke by 35% compared with well-controlled warfarin, irrespective of a patient's stroke risk Comparable to Lovenox in the prevention of major venous thromboembolism (VTE) and VTE-related mortality after both knee and hip replacement, according to RE-NOVATE data Equal efficacy to well-controlled warfarin in the treatment of acute VTE, but with a 37% reduction in major or clinically relevant bleeding risk over 6 months, according to RECOVER data |
2楼2013-04-03 10:38:46
13楼2013-04-09 19:00:34
★ ★ ★ ★ ★ ★
小木虫: 金币+0.5, 给个红包，谢谢回帖
williamxiang: 金币+5 2013-04-03 10:47:53
小木虫: 金币+0.5, 给个红包，谢谢回帖
williamxiang: 金币+5 2013-04-03 10:47:53
|
Weaknesses A superiority claim over warfarin in stroke prevention was rejected for inclusion in the label by the FDA A 110 mg doseage was not approved for use in patients at higher bleeding risk A higher risk of myocardial infarction was seen in RE-LY Twice daily dosing, compared with once daily for Xarelto Not approved in the US for VTE prevention post-surgery, unlike Xarelto which was approved in July 2011 Has faced some safety concerns, and the label was updated to mandate renal testing in high-risk patients Associated with a 6% rate of major gastrointestinal hemorrhage during each patient year on treatment Other gastrointestinal side effects, including dyspepsia, nausea and gastritis, are increased compared with warfarin (35% vs 24%) Current lack of antidote Very short half-life once removed from specially designed desiccant-containing packaging |
3楼2013-04-03 10:41:12
★
小木虫: 金币+0.5, 给个红包，谢谢回帖
小木虫: 金币+0.5, 给个红包，谢谢回帖
|
Opportunities Approval in AF opens up a blockbuster market, and Pradaxa could garner a greater share of the market in the near term due to its first mover advantage Pradaxa could be viewed as superior to Xarelto given Xarelto's lack of superiority to warfarin on an intent-to-treat basis seen in the ROCKET AF trial Despite the proven efficacy of warfarin in stroke prevention, it has a number of limitations, such as an increased risk of bleeding and the need for patient monitoring and dose adjustment, which has created an unmet need for safe and effective alternatives Approval in acute coronary syndrome (ACS); phase III trials in this setting began in December 2007 Development of competitor Eliquis in ACS was discontinued following high rates of bleeding in trials High cost and considerable copay required for Pradaxa may fade as insurers realize potential savings from increased avoidance of ischemic events and hospitalization AF is the most common sustained cardiac rhythm disturbance, and prevalence increases with age Up to 60% of cases of AF are caused by hypertension or coronary artery disease, which are increasing in prevalence in most Western societies ACS is the leading cause of death in the US and one of the most prevalent non-communicable diseases in the world |
4楼2013-04-03 10:53:35
★ ★ ★ ★
williamxiang: 金币+4 2013-04-03 13:01:31
williamxiang: 金币+4 2013-04-03 13:01:31
|
Threats Commercial threat from Eliquis; current phase III data appear to support a superiority claim over warfarin which would differentiate the product Increased competition in the oral anticoagulant category; the marketing battle between Pradaxa, Xarelto and Eliquis will be key In Japan, Lixiana is in development for stroke prevention in AF, and could present competition in this market following Pradaxa's launch in March 2011 The drug may not gain approval in ACS given concerns about bleeding If approved, use in ACS may be limited given the availability of new, more potent antiplatelet regimes, such as AstraZeneca's Brilinta, that improve outcomes with less increased bleeding Physicians may be reluctant to switch patients who are well controlled on warfarin to other treatment options Price: the significant price difference between Pradaxa and warfarin could present reimbursement issue Self administration of low-molecular-weight heparins out of hospital by patients with AF undergoing elective cardioversion is a promising approach that may result in cost savings Low-molecular-weight heparins, in particular enoxaparin which presents a generic and efficacious option for DVT treatment and prophylaxis following orthopedic surgery |
5楼2013-04-03 10:54:50
6楼2013-04-03 10:56:14
7楼2013-04-03 11:15:17
8楼2013-04-03 13:02:42
10楼2013-04-04 00:54:08
11楼2013-04-06 12:19:13
12楼2013-04-06 21:54:49
14楼2013-04-10 00:30:10
15楼2013-04-11 20:08:46
16楼2013-04-26 06:35:02
17楼2013-09-03 16:57:58
18楼2013-09-10 18:04:01